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The prevalence of type 2 diabetes mellitus is increasing rapidly, and its treatment with
pioglitazone is likely to induce rhabdomyolysis. We aimed to determine the effect of
cotreatment with pioglitazone and red mold dioscorea (RMD) produced by Monascus
purpureus NTU 568 on pancreas function in streptozotocin (STZ)-induced diabetic rats. In
diabetic rats fed RMD, RMD with pioglitazone, and pioglitazone alone, insulin concentra-
tions increased significantly by 18.6e40.4%, 64.0e100.0%, and 52.8%, respectively,
compared with that in the diabetic group (p < 0.05). Oral glucose tolerance was impaired in
the STZ-induced diabetic group within 4 weeks, however, oral glucose tolerance in rats
treated with RMD or RMD with pioglitazone improved after 4 weeks, 6 weeks, and 8 weeks.
Findings from this study might lend support to the use of RMD as a novel functional food
for the prevention of diabetes.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
 
Open access under CC BY-NC-ND license.1. Introduction
The prevalence of type 2 diabetes mellitus (DM2) is increasing
rapidly in most parts of the world [1], which will result in an
increase in the complications associated with this disease.
Currently, this condition is often treated with pioglitazone. In
individuals with DM2, insulin sensitivity is often less than half
of that of average healthy individuals with normal glucose
tolerance. Insulin resistance (IR) is the major finding for
several metabolic disorders, including metabolic syndrome,chemical Science and T
10617, Taiwan.
. Pan).
ministration, Taiwan. PublDM2, dyslipidemia, hyperglycemia, and hypertension, and is
an independent predictor of cardiovascular disease [2,3],
although responsiveness to insulin may vary considerably
between different adipose depots. The resulting elevated
circulating free fatty acid levels disrupt the glucoseefatty acid
(Randle) cycle, aggravating IR in the muscle and liver, and
resulting in insulin-induced suppression of hepatic glyco-
genolysis. IR is indeed a pathogenetic element that plays a key
role in the development of metabolic and hemodynamic al-
terations, and is responsible, in turn, for the onset of the so-
called cardiometabolic syndrome [4]. Given tissueechnology, College of Life Science, National Taiwan University,
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 3 ( 2 0 1 5 ) 7 1 9e7 2 8720differences in insulin dependence and sensitivity, manifes-
tations of IR syndrome are likely to reflect the composite ef-
fects of excess insulin and variable resistance to its actions
[5,6].
The major site of impaired insulin-stimulated glucose
utilization is skeletal muscle, which in DM2 shows reductions
in glucose uptake, glycogenesis, and glucose oxidation [3,7].
According to the Naranjo probability scale, it is likely that
pioglitazone will induce rhabdomyolysisdthe rapid break-
down ofmuscle cells with the release of intracellular contents
into the circulation [8]. This conclusion was based on the
exclusion of potential medical causes, such as hypothyroid-
ism, infection, muscle trauma, alcoholism, patient's drug
exposure, and observed resolution of signs and symptoms
when pioglitazone was withdrawn [9]. Similarly, statins,
which form the most widely prescribed class of cholesterol-
lowering drugs [10], may also lead to rhabdomyolysis via a
variety of mechanisms [11]. Statins inhibit 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, thereby
decreasing the conversion of HMG-CoA to mevalonate, the
rate-limiting step of cholesterol biosynthesis [12]. Improved
treatment of hyperglycemia, and other risk factors associated
with DM2 and metabolic syndrome is thus required, because
this would make it possible to markedly lower the risk of both
micro- and macrovascular complications [13].
Monascus species of fungus have been used in preparing
traditional foods in Eastern Asia for several centuries. In our
previous studies, we showed that Monascus-fermented rice,
known as red mold rice (RMR), demonstrates antioxidative
effects [14] and is useful in the treatment of Alzheimer's dis-
ease [15]. Moreover, dioscorea, a traditional Chinese herb, is
regarded as a functional food because it contains many
beneficial ingredients that help in the prevention of various
diseases [16]. Dioscorea is an ideal substrate for Monascus
fermentation. It has been reported that red mold dioscorea
(RMD) is a stronger HMG-CoA reductase inhibitor with a
higher hypocholesterolemic activity than RMR [17]. Further-
more, we previously found that RMD exerts a greater antidi-
abetic effect than traditional RMR in streptozotocin (STZ)-
induced rats [18].
In the present study, we used STZ-induced rats to inves-
tigate the effect of oral administration of a small amount of
RMD or RMD along with pioglitazone on the liver somatic
index, kidney index, and muscle index. Plasma electrolytes
were also examined to investigate the safety of the combi-
nation ofMonascus-fermented products and pioglitazone, and
the risk of rhabdomyolysis.2. Materials and methods
2.1. Preparation of RMD
Monascus purpureus NTU 568 was isolated in our laboratory.
The strain culture was maintained on Potato Dextrose Agar
(PDA) slant at 10C and transferred monthly. The dioscorea
root (Dioscorea batatas Dence) purchased from a local super-
market in Taiwanwas used to produce RMD using themethod
of solid-state culture [14]. Briefly, a 500-g substratewas soaked
in distilled water for 8 hours. After that, excess water wasremoved with a sieve. The substrate was autoclaved for 20
minutes at 121C in a “koji-dish” (the koji-dish was made of
wood with the dimensions of 30 cm  20 cm  5 cm). After
having been cooled, the substrate was inoculated with 5% (v/
w) spore suspension (1  105 spores/mL) of M. purpureus NTU
568. The inoculated substrate was cultivated at 30C for 10
days. During the culturing stage, 100 mL of water was added
daily to the substrate from the 2nd day to the 5th day. At the
end of cultivation, the crushed and dried product with the
mold was used for the experiments [19].
2.2. Animals and diets
Male Sprague-Dawley rats, weighing 140e160 g, aged
5e6 weeks, were used for this experiment. The experiments
were carried out in a qualified animal breeding room in the
Animal Center at our institute (protocol complied with
guidelines described in the “Animal Protection Law,” amen-
ded on June 29, 2011, Hua-Zong-(1)-Yi-Tzi-10000136211,
Council of Agriculture, Executive Yuan, Taiwan, R.O.C.). Dia-
betes was induced by injecting the rats intraperitoneally with
65 mg/kg STZ (Sigma Chemical Co., St Louis, MO, USA) in 0.1M
acetate buffer and 230 mg/kg nicotinamide after fasting for
12e24 hours. Rats with a plasma glucose concentration of
200 mg/dL were considered as diabetic animals and used in
this study. The animals were randomly divided into nine
groups and each group contained nine animals.
2.3. Determination of monascin and ankaflavin
concentrations
The RMD powder (1 g) was extracted with 10 mL of methanol
at 60C for 30 minutes. The extract was further filtered with a
0.45-mm filter and analyzed using high-performance liquid
chromatography. High-performance liquid chromatography
analyses were performed on a LC-2000 series (Jasco, Tokyo,
Japan) apparatus with a PU-2089 plus pump and an MD-2010
plus diode array detector, equipped with a LUNA C18 column
(250  4.6 mm inner diameter, 5 mm particle size; Phenom-
enex, Torrance, CA, USA). Wavelength of the diode array de-
tector was set at 238 nm. The analytical method was based on
our previous study [14].
2.4. Dose and grouping
The dose of RMD powder and pioglitazone was calculated in
accordance with Boyd's formula of body surface area, as rec-
ommended by the Food and Drug Administration [20]. The
recommended and used daily dietary dose of commercial
Monascus-fermented product is usually 1.0e2.0 g for an adult
[21,22]. The use of 15 mg of monascin as the Department of
Health, Executive Yuan, R.O.C. (Taiwan) maximum dosage of
an adult per day to calculate the rat dose has been proved to
exhibit a hypolipidemic effect [23]. Pioglitazone used as a
positive hypoglycemic (antihyperglycemic, antidiabetic) drug
also has a recommended dose of 30 mg/d for an adult.
Therefore, RMD and pioglitazone are used as the reference
dose for an adult with a weight of 65 kg and a height of 170 cm.
These dosages were used as a frame of reference for the
conversion of the dose into a type 2 diabetes animalmodel. All
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and orally administered to the rats using a stomach tube for 8
weeks.
2.5. Experimental groups and treatments
The animals were randomly divided into eight treatment
groups, and each group contained nine animals. The effects of
different doses of RMD on diabetic development were evalu-
ated in STZ-induced diabetic rats receiving an oral adminis-
tration of RMD. Age-matched normal rats served as normal
control (C). Diabetic rats were divided into eight groups: Group
1ddiabetic control (DC); Group 2 received a onefold dose of
RMD [176 mg/kg body weight (bw)/d including 1.2 mg mon-
ascin and 0.6 mg ankaflavin] (D1R); Group 3 received a twofold
dose of RMD (352 mg/kg bw/d including 2.4 mg monascin and
1.2 mg ankaflavin) (D2R); Group 4 received a fivefold dose of
RMD (880 mg/kg bw/d including 6.0 mg monascin and 3.0 mg
ankaflavin) (D5R); Group 5 received pioglitazone 2.6 mg/kg
(DM); Group 6 received one dose of RMD (176 mg/kg bw/
d including 1.2 mg monascin and 0.6 mg ankaflavin) and
pioglitazone 2.6 mg/kg (D1RM); Group 7 received a twofold
dose of RMD (352 mg/kg bw/d including 2.4 mg monascin and
1.2 mg ankaflavin) and pioglitazone 2.6 mg/kg (D2RM); and
Group 8 received a fivefold dose of RMD (880 mg/kg bw/
d including 6.0 mg monascin and 3.0 mg ankaflavin) and
pioglitazone 2.6 mg/kg (D5RM). Rats were anesthetized and
sacrificed at the end of the 8-week treatment.
2.6. Oral glucose tolerance test
The oral glucose tolerance test (OGTT) was performed every 2
weeks. The experiment was performed on animals after
fasting for 12 hours (free access to water). Animals were given
glucose (2 g/kg bw) with an oral cannula [24]. Blood samples
were collected from the tail vein at 0 minute, 30 minutes, 60
minutes, 90 minutes, 120 minutes, 150 minutes, and 180 mi-
nutes after glucose administration. Blood glucose, lipid, urea,
and plasma insulin levels were measured at the end of 8
weeks of RMD treatment. Blood glucose was determined
immediately using the glucose oxidase method, using an
analyzer [25].
2.7. Serum lipid analysis
Serum total cholesterol (TC), triglyceride (TG), and high-
density lipoprotein cholesterol (HDL-C) levels were
measured in triplicate using commercial enzymatic kits.
These kits were as follows: the TC assay kit (CH 200; Randox
Laboratories Ltd, Antrim, UK), the TG assay kit (TR-210; Ran-
dox Laboratories Ltd), and the HDL-C assay kit (CH-203; Ran-
dox Laboratories Ltd). Serum low-density lipoprotein
cholesterol (LDL-C) levels were estimated using the following
equation [26]: LDL-C (mg/dL) ¼ TC  TG/5  HDL-C.
2.8. Plasma liver, kidney, electrolyte, and creatine
phosphokinase analyses
Plasma aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase (ALP), total protein,blood urea nitrogen (BUN), creatinine, sodium, potassium,
chloride, calcium, phosphorous, and creatine phosphokinase
(CPK) levels were measured in triplicate using an automatic
biochemical analyzer (Beckman-700; Beckman, Fullerton, CA,
USA).
2.9. Statistical analysis
Data are expressed as the mean ± standard deviation. Statis-
tical significance of the biochemical effects was determined
by one-way analysis of variance using the general linear
model procedure of SPSS software (SPSS Institute, Inc., Chi-
cago, IL, USA), followed by analysis of variance using the
Duncan's test. Differences with p < 0.05 were considered sta-
tistically significant.3. Results
3.1. Changes in body weight and daily dietary intake of
STZ-induced rats
We investigated the effect of RMD on the development of
diabetes and body weight of the same animal model over an
extended period (8 weeks). In this experiment, pioglitazone
was used to prevent the progression of diabetes. Body weight
of the vehicle-treated STZ-induced rats was lower than that in
the other groups (Fig. 1A). After 8 weeks of being fed RMD, the
daily food and water intake of the vehicle-treated STZ-
induced rats was higher than that of the other groups (Fig. 1B
and 1C). In addition, the exterior appearance and health of all
experimental animals presented as normal.
3.2. Effect of RMD on the blood glucose level during
OGTT
OGTT measures the body's ability to use glucose, which is the
main source of energy, and can be used to diagnose predia-
betes and diabetes. It is a screening test for diabetes that in-
volves testing an individual's plasma glucose level after
drinking a solution containing 2 g/kg bw of glucose. In-
dividuals with a plasma glucose level of <200 mg/dL but
140 mg/dL are diagnosed as having impaired glucose toler-
ance or prediabetes. Fig. 2 depicts the hypoglycemic effect of a
single oral administration of variable amounts of RMD on the
OGTT results of STZ-induced diabetic rats. OGTT results
indicated impaired glucose tolerance in the STZ-induced
diabetic group within 4 weeks. The blood glucose concentra-
tions in the groups treatedwith RMDor RMDwith pioglitazone
were improved after 4 weeks, 6 weeks, and 8 weeks (Fig.
2BeD). In the 8th week, we measured the blood glucose
levels after 120 minutes. The blood glucose level in the DC
group, which was up to 452 mg/dL, was significantly higher
than that in the C group (120 mg/dL). After feeding with RMD,
RMDepioglitazone, or pioglitazone, blood glucose concentra-
tions were significantly lowered by 8.0e13.1%, 14.3e19.9%,
and 9.9%, respectively (p < 0.05; Fig. 2D). Rats treated with oral
administration of RMD for 8 weeks showed enhanced oral
glucose tolerance and blood glucose regulation than those
receiving pioglitazone.
Fig. 1 e Effectof singleoral administrationofRMDon (A)bodyweight, (B) food intake, and (C)water intake inexperimentalSTZ-
induced diabetic rats. Sprague-Dawley rats fed a normal diet without the administration of RMD were used as control group
(the C group;C). The diabetic ratswere fed a normal diet without the administration of RMD (the DC group;B). The other rats
with diabetes were administered a onefold dose of RMD [the D1R group; 176 mg/kg body weight (bw)/d including 1.2 mg
monascin and 0.6mgankaflavin;;], a twofold dose of RMD (theD2R group; 352mg/kgbw/d including 2.4mgofmonascin and
1.2 mg ankaflavin;△), and a fivefold dose of RMD (the D5R group; 880 mg/kg bw/d including 6.0 mg of monascin and 3.0 mg
ankaflavin;-). The DM group (▫), a positive control group,was orally given pioglitazone 2.6mg/kg bw/d. D1RM (A), D2RM (◊),
and D5RM (:) were fed the normal diet and orally given pioglitazone (2.6 mg/kg bw/d) with a one-, two-, and fivefold dose of
RMD, respectively. Each value is expressed as mean ± SD (n¼ 9). * Significantly different (p < 0.05) versus the DC group.
bw¼ body weight; C¼ SpragueeDawley rats fed normal diet; DC¼ streptozotocin-induced diabetic rats fed normal diet;
DM¼ streptozotocin-induceddiabetic rats fednormal diet andadministeredwithpioglitazone; D1R¼ streptozotocin-induced
diabetic rats fed normal diet and administeredwith redmold dioscorea (1£, 176mg/kg bw/d including 1.2 mgmonascin and
0.6mgankaflavin); D2R¼ streptozotocin-induceddiabetic rats fednormal diet andadministeredwith redmolddioscorea (2£,
352mg/kg bw/d including 2.4mg ofmonascin and 1.2mg ankaflavin); D5R¼ streptozotocin-induced diabetic rats fed normal
diet and administered with red mold dioscorea (5£, 880 mg/kg bw/d including 6.0 mg of monascin and 3.0 mg ankaflavin);
D1RM¼ streptozotocin-induced diabetic rats fed normal diet and administeredwith redmold dioscorea (1£, 176mg/kg bw/d
including 1.2 mgmonascin and 0.6 mg ankaflavin) and pioglitazone 2.6 mg/kg; D2RM¼ streptozotocin-induced diabetic rats
fed normal diet and administered with red mold dioscorea (2£, 352 mg/kg bw/d including 2.4 mgmonascin and 1.2 mg
ankaflavin) and pioglitazone 2.6 mg/kg; D5RM¼ streptozotocin-induced diabetic rats fed normal diet and administered with
red mold dioscorea (5£, 880 mg/kg bw/d including 6.0 mg of monascin and 3.0 mg ankaflavin) and pioglitazone 2.6 mg/kg;
RMD¼ red mold dioscorea; SD¼ standard deviation; STZ¼ streptozotocin.
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glycated hemoglobin of STZ-induced diabetic rats
In diabetic rats fed RMD (1-, 2-, or 5-fold dose), RMD (1-, 2-, or
5-fold dose) with pioglitazone, and pioglitazone alone, insulin
concentrations increased significantly by 18.6e40.4%,
64.0e100.0%, and 52.8%, respectively, compared with that in
the diabetic group (p < 0.05; Table 1). The levels of fasting
serum insulin in the vehicle-treated STZ-induced diabetic rats
were lower than those in other groups receiving RMD or
RMDepioglitazone treatment.The hypoglycemic effect of RMD on the blood glucose
levels of the STZ-induced diabetic rats was particularly
noticeable during the latter part of the experiment. The gly-
cated hemoglobin test is an important blood test used to
determine how well diabetes is being controlled. Glycated
hemoglobin provides an average of blood sugar control over a
4e12-week period, and is used in conjunction with a home
blood sugar monitoring device to guide adjustments to a dia-
betes medicine regime. In our study, diabetic rats showed
elevated glycated hemoglobin levels (Table 1). Feeding these
rats RMD or RMDwith pioglitazone resulted in stabilization of
Fig. 2 e Effect of RMD on the blood glucose level of STZ-induced diabetic rats. During the experimental period, blood samples
were collected to quantify the blood glucose levels at (A) 2 weeks, (B) 4 weeks, (C) 6 weeks, and (D) 8 weeks. The various
symbols used in this figure represent the same groups as those shown in Fig. 1. Each value is expressed as mean ± SD
(n ¼ 9). *Significantly different (p < 0.05) versus the DC group. RMD ¼ red mold dioscorea; SD ¼ standard deviation;
STZ ¼ streptozotocin.
Table 1 e Effects of RMD powder on experimental STZ-induced diabetic rats, performance serum BUN, creatinine, glycated
hemoglobin, insulin, and CPK.
Group BUN Creatinine Glycated hemoglobin Insulin CPK
(mg/dL) (U/L) (IU/mL) (U/L)
C 26.9 ± 0.5* 0.66 ± 0.11 4.13 ± 0.07* 42.6 ± 1.3* 467.5 ± 12.4
DC 47.1 ± 0.8 0.51 ± 0.07 7.73 ± 0.71 16.1 ± 1.3 576.6 ± 21.3
D1R 39.1 ± 2.2* 0.55 ± 0.06 6.23 ± 0.49* 19.1 ± 1.1* 491.3 ± 24.5
D2R 37.1 ± 4.2* 0.51 ± 0.08 5.96 ± 0.43* 20.3 ± 1.8* 489.2 ± 10.0
D5R 26.9 ± 9.9* 0.55 ± 0.05 5.80 ± 0.59* 22.6 ± 1.6* 487.2 ± 11.5
DM 30.4 ± 1.5* 0.52 ± 0.05 6.18 ± 0.64* 24.6 ± 1.7* 479.7 ± 23.3
D1RM 34.1 ± 5.2* 0.58 ± 0.08 5.96 ± 0.31* 26.4 ± 2.5* 487.0 ± 12.2
D2RM 32.1 ± 2.2* 0.57 ± 0.09 5.93 ± 0.23* 28.9 ± 1.5* 490.5 ± 12.6
D5RM 31.1 ± 2.6* 0.58 ± 0.07 5.76 ± 0.13* 32.2 ± 2.4* 489.6 ± 12.7
Data are presented as mean ± SD (n ¼ 9).
*Significantly different (p < 0.05) versus the DC group.
BUN ¼ blood urea nitrogen; C ¼ SpragueeDawley rats fed normal diet; CPK ¼ creatinine phosphokinase; DC ¼ streptozotocin-induced diabetic
rats fed normal diet; DM ¼ streptozotocin-induced diabetic rats fed normal diet and administered with pioglitazone; D1R ¼ streptozotocin-
induced diabetic rats fed normal diet and administered with red mold dioscorea (1, 176 mg/kg body weight(bw)/d including 1.2 mg monascin
and 0.6 mg ankaflavin); D2R ¼ streptozotocin-induced diabetic rats fed normal diet and administered with red mold dioscorea (2, 352 mg/kg
bw/d including 2.4 mg of monascin and 1.2 mg ankaflavin); D5R ¼ streptozotocin-induced diabetic rats fed normal diet and administered with
red mold dioscorea (5, 880 mg/kg bw/d including 6.0 mg of monascin and 3.0 mg ankaflavin); D1RM ¼ streptozotocin-induced diabetic rats fed
normal diet and administered with redmold dioscorea (1, 176 mg/kg bw/d including 1.2 mgmonascin and 0.6 mg ankaflavin) and pioglitazone
2.6 mg/kg; D2RM ¼ streptozotocin-induced diabetic rats fed normal diet and administered with red mold dioscorea (2, 352 mg/kg bw/
d including 2.4 mg monascin and 1.2 mg ankaflavin) and pioglitazone 2.6 mg/kg; D5RM ¼ streptozotocin-induced diabetic rats fed normal diet
and administeredwith redmold dioscorea (5, 880mg/kg bw/d including 6.0mg ofmonascin and 3.0mg ankaflavin) and pioglitazone 2.6mg/kg;
RMD ¼ red mold dioscorea; SD ¼ standard deviation; STZ ¼ streptozotocin.
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levels lower than that in the DC group.3.4. Effect of RMD on blood lipid levels
TGs play an important role as transporters of lipids in the
blood. However, excessive TG levels are associated with pre-
disposition to cardiovascular disease. As shown in Table 2, the
RMD-treated or RMD with pioglitazone cotreated groups of
STZ-induced diabetic rats had lower TG levels (26.1e42.4%;
p< 0.05) comparedwith the diabetic group. High TC levelsmay
lead to occluded blood vessels and accelerated atheroscle-
rosis. The RMD-treated and RMD with pioglitazone cotreated
groups of diabetic rats displayed statistically significantly
lower TC values than the DC groups (15.7e23.6%; p < 0.05).
HDL-C enables mobilization of cholesterol back to the liver
for breakdown and has vascular protective effects, and a
higher content of this lipoproteinmay reduce the incidence of
cardiovascular disease. Diabetic rats that had been treated
with RMD displayed dose-dependently higher HDL-C levels
than the rats of the DC group. High levels of LDL-C accumulate
in the walls of blood vessels and contribute to atherosclerosis.
Therefore, LDL-C is an important indicator for the prediction
of coronary heart disease. No significant differences were
observed in the LDL-C levels after concomitant administration
of RMDor RMDwith pioglitazone to STZ-induced diabetic rats.
We also calculated the ratio of TC/HDL-C, which are indices of
ischemic heart disease risk in humans. In diabetic rats fed
RMD (1-, 2-, or 5-fold dose), RMD (1-, 2-, or 5-fold dose) with
pioglitazone, and pioglitazone alone, the TC/HDL-C ratio
decreased significantly compared with that in the diabetic
group (p < 0.05; Table 2).Table 2 e Effects of RMD powder on the levels of serum TG, TC
rats.
Groups TG TC
(mg/dL
C 86.3 ± 3.1* 86.7 ± 2.1*
DC 229.5 ± 6.3 94.5 ± 4.9
D1R 169.7 ± 2.2* 77.7 ± 1.8*
D2R 156.7 ± 2.9* 76.7 ± 1.8*
D5R 136.1 ± 3.9* 72.2 ± 2.1*
DM 198.1 ± 6.4* 86.8 ± 2.4*
D1RM 168.5 ± 3.6* 79.7 ± 1.6*
D2RM 151.5 ± 4.3* 75.7 ± 2.3*
D5RM 132.1 ± 4.9* 74.8 ± 2.8*
Data are presented as mean ± SD (n ¼ 9).
*Significantly different (p < 0.05) versus the DC group.
C¼ SpragueeDawley rats fed normal diet; DC¼ streptozotocin-induced di
fed normal diet and administeredwith pioglitazone; D1R¼ streptozotocin
dioscorea [1, 176 mg/kg body weight(bw)/d including 1.2 mgmonascin a
normal diet and administered with red mold dioscorea (2, 352 mg
D5R ¼ streptozotocin-induced diabetic rats fed normal diet and administe
monascin and 3.0 mg ankaflavin); D1RM ¼ streptozotocin-induced diabet
176mg/kg bw/d including 1.2 mgmonascin and 0.6 mg ankaflavin) and pio
normal diet and administered with redmold dioscorea (2, 352mg/kg bw
2.6mg/kg; D5RM¼ streptozotocin-induceddiabetic rats fednormal diet an
6.0 mg of monascin and 3.0 mg ankaflavin) and pioglitazone 2.6 mg/kg; H
poprotein cholesterol; RMD ¼ red mold dioscorea; SD ¼ standard deviatio3.5. Safety assessment: plasma liver function tests
Because the majority of commercially available red mold
fermented products contain citrinin, a hepato- and neph-
rotoxin, we assessed the safety of products by measuring the
levels of AST and ALT in blood (plasma). As shown in Table 3,
AST and ALT levels were found to increase significantly in the
plasma of the vehicle-treated STZ-induced rats; these eleva-
tions were decreased virtually to control levels in all the RMD-
treated groups. We also determined the concentrations of
ALP, which is abundant in the kidneys, intestine, and liver, as
well as total protein. Serum ALP activity is frequently
requested in clinical routine, mostly to estimate skeletal and
hepatobiliary status. The RMD-treated or RMD with pioglita-
zone cotreated groups of STZ-induced diabetic rats had lower
ALP levels (p < 0.05) than the diabetic group. This finding
suggests that RMD or RMD with pioglitazone could improve
liver function by decreasing AST, ALT and ALP enzymes ac-
tivities in STZ-induced diabetic rats.3.6. Safety assessment: examination of renal function,
electrolyte balance, and CPK concentrations in STZ-induced
diabetic rats
BUN is a protein metabolite; its high concentrations indicate
impaired renal excretion. The first clinical manifestations of
diabetes involve increased proteinuria, followed by gradual
increases in serum urea nitrogen and creatinine, and finally
uremia. BUN levels in the STZ-induced diabetic rats in the
RMD-treated groups decreased significantly after dosing
(Table 1). In the normal group, BUN was not abnormal,
whereas in the diabetes (DC) group, BUN concentrations were, HDL-C, and LDL-C in experimental STZ-induced diabetic
HDL-C LDL-C TC/HDL-C
)
59.2 ± 6.8 10.7 ± 3.6 1.5 ± 0.05
56.5 ± 1.3 9.0 ± 1.4 1.7 ± 0.21
60.8 ± 3.3 14.5 ± 4.1 1.3 ± 0.26*
63.8 ± 3.3 12.5 ± 4.1 1.2 ± 0.26*
62.6 ± 6.2 10.0 ± 1.8 1.2 ± 0.07*
65.6 ± 3.1 20.6 ± 1.9 1.3 ± 0.27*
63.7 ± 8.7 12.3 ± 2.5 1.3 ± 0.17*
64.7 ± 8.7 10.3 ± 2.5 1.2 ± 0.17*
66.5 ± 9.7 8.5 ± 3.5 1.1 ± 0.18*
abetic rats fed normal diet; DM¼ streptozotocin-induced diabetic rats
-induced diabetic rats fed normal diet and administeredwith redmold
nd 0.6 mg ankaflavin]; D2R ¼ streptozotocin-induced diabetic rats fed
/kg bw/d including 2.4 mg of monascin and 1.2 mg ankaflavin);
red with red mold dioscorea (5, 880 mg/kg bw/d including 6.0 mg of
ic rats fed normal diet and administered with red mold dioscorea (1,
glitazone 2.6 mg/kg; D2RM¼ streptozotocin-induced diabetic rats fed
/d including 2.4 mgmonascin and 1.2 mg ankaflavin) and pioglitazone
d administeredwith redmold dioscorea (5, 880mg/kg bw/d including
DL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density li-
n; STZ ¼ streptozotocin; TC ¼ total cholesterol; TG ¼ triglyceride.
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tion in diabetic rats. Regardless of whether the rats were
treated with RMD or RMD and pioglitazone, treatment resul-
ted in a significant reduction in the concentration of BUN;
thus, RMD protects kidney function. During rhabdomyolysis,
damaged muscle cells release CPK. CPK levels are often used
in the diagnosis and monitoring of clinical myocardialTable 3 e Effects of RMD powder on the levels of plasma AST,
diabetic rats.
Groups AST ALT
(U/L)
C 127.5 ± 3.3* 72.7 ± 3.8*
DC 457.5 ± 2.1 297.5 ± 2.1
D1R 185.0 ± 3.4* 121.3 ± 3.6*
D2R 173.0 ± 1.4* 119.3 ± 3.6*
D5R 152.6 ± 8.4* 108.3 ± 4.1*
DM 184.0 ± 8.4* 120.6 ± 5.9*
D1RM 169.3 ± 3.2* 113.8 ± 5.9*
D2RM 164.3 ± 3.2* 103.8 ± 5.9*
D5RM 142.6 ± 3.5* 91.2 ± 2.8*
Data are presented as mean ± SD (n ¼ 9).
*Significantly different (p < 0.05) versus the DC group.
ALP ¼ alkaline phosphatase; ALT ¼ alanine transaminase; AST ¼ as
DC ¼ streptozotocin-induced diabetic rats fed normal diet; DM ¼ strepto
pioglitazone; D1R¼ streptozotocin-induced diabetic rats fed normal diet a
(bw)/d including 1.2mgmonascin and 0.6mg ankaflavin]; D2R¼ streptozo
mold dioscorea (2, 352 mg/kg (bw)/d including 2.4 mg of monascin and
normal diet and administered with red mold dioscorea (5, 880 mg/
D1RM ¼ streptozotocin-induced diabetic rats fed normal diet and adminis
monascin and 0.6 mg ankaflavin) and pioglitazone 2.6 mg/kg; D2RM ¼ st
with red mold dioscorea (2, 352 mg/kg (bw)/d including 2.4 mg monasc
tozotocin-induced diabetic rats fed normal diet and administered with re
and 3.0 mg ankaflavin) and pioglitazone 2.6 mg/kg; RMD ¼ red mold dios
Table 4 e Effects of RMD powder on the levels of serum sodium
experimental STZ-induced diabetic rats.
Groups Sodium Potassium
(mEq/L)
C 152.6 ± 0.2* 7.9 ± 0.5*
DC 142.4 ± 0.8 12.1 ± 1.6
D1R 152.3 ± 0.7* 7.6 ± 0.5*
D2R 149.1 ± 1.1* 8.2 ± 0.5*
D5R 149.9 ± 1.2* 8.1 ± 0.4*
DM 151.1 ± 1.4* 8.6 ± 0.6*
D1RM 152.4 ± 0.9* 8.8 ± 0.4*
D2RM 150.5 ± 0.7* 8.6 ± 0.6*
D5RM 149.1 ± 1.1* 8.5 ± 0.8*
Data are presented as mean ± SD (n ¼ 9).
*Significantly different (p < 0.05) versus the DC group.
C ¼ Sprague-Dawley rats fed normal diet; DC¼ streptozotocin-induced dia
fed normal diet and administered with pioglitazone; D1R ¼ streptozotoc
mold dioscorea [1, 176 mg/kg body weight (bw)/d including 1.2 mg mon
rats fed normal diet and administered with red mold dioscorea (2, 352
D5R¼ streptozotocin-induced diabetic rats fed normal diet and administe
monascin and 3.0 mg ankaflavin); D1RM ¼ streptozotocin-induced diabeti
176 mg/kg (bw)/d including 1.2 mg monascin and 0.6 mg ankaflavin) and
fed normal diet and administered with red mold dioscorea (2, 352 mg/k
glitazone 2.6 mg/kg; D5RM ¼ streptozotocin-induced diabetic rats fed no
(bw)/d including 6.0 mg of monascin and 3.0 mg ankaflavin) and pioglitaz
STZ ¼ streptozotocin.infarction and muscle diseases. Table 1 shows that STZ-
induced diabetic rats administered a one-, two-, or fivefold
dose of RMD or RMD with pioglitazone did not exhibit any
significant increase in their CPK levels.
Serum electrolytes were also compared between different
rat groups (Table 4); the rats in the vehicle-treated STZ-
induced group had lower sodium and chloride levels, andALT, ALP, and total proteins in experimental STZ-induced
ALP Total protein
(IU/L) (g/dL)
132.1 ± 2.4* 7.6 ± 0.2
144.3 ± 2.1 8.5 ± 0.4
135.8 ± 2.7* 7.9 ± 0.2
133.5 ± 2.8* 8.0 ± 0.3
131.5 ± 2.7* 7.8 ± 0.5
134.8 ± 3.1* 7.6 ± 0.4
132.3 ± 3.4* 8.2 ± 0.2
132.1 ± 2.6* 7.8 ± 0.3
131.6 ± 3.4* 7.5 ± 0.2
partate transaminase; C ¼ SpragueeDawley rats fed normal diet;
zotocin-induced diabetic rats fed normal diet and administered with
nd administered with redmold dioscorea [1, 176mg/kg body weight
tocin-induced diabetic rats fed normal diet and administeredwith red
1.2 mg ankaflavin); D5R ¼ streptozotocin-induced diabetic rats fed
kg (bw)/d including 6.0 mg of monascin and 3.0 mg ankaflavin);
tered with red mold dioscorea (1, 176 mg/kg (bw)/d including 1.2 mg
reptozotocin-induced diabetic rats fed normal diet and administered
in and 1.2 mg ankaflavin) and pioglitazone 2.6 mg/kg; D5RM ¼ strep-
d mold dioscorea (5, 880 mg/kg (bw)/d including 6.0 mg of monascin
corea; SD ¼ standard deviation; STZ ¼ streptozotocin.
, potassium, chloride, calcium, and phosphorus in
Chloride Calcium Phosphorus
(mg/dL)
94.5 ± 2.1* 12.4 ± 0.7 14.3 ± 1.3
83.2 ± 1.4 12.1 ± 0.4 14.2 ± 2.5
89.5 ± 1.5* 12.3 ± 0.3 14.1 ± 1.2
90.1 ± 1.3* 12.2 ± 0.5 14.5 ± 1.7
92.3 ± 1.4* 12.4 ± 0.2 14.7 ± 1.6
91.9 ± 2.3* 12.6 ± 0.8 13.9 ± 2.3
92.6 ± 1.2* 12.4 ± 0.5 14.6 ± 2.6
92.5 ± 1.4* 12.5 ± 0.7 14.4 ± 3.6
93.3 ± 1.3* 12.4 ± 0.6 14.5 ± 2.4
betic rats fed normal diet; DM ¼ streptozotocin-induced diabetic rats
in-induced diabetic rats fed normal diet and administered with red
ascin and 0.6 mg ankaflavin]; D2R ¼ streptozotocin-induced diabetic
mg/kg (bw)/d including 2.4 mg of monascin and 1.2 mg ankaflavin);
red with redmold dioscorea (5, 880 mg/kg (bw)/d including 6.0 mg of
c rats fed normal diet and administered with red mold dioscorea (1,
pioglitazone 2.6 mg/kg; D2RM ¼ streptozotocin-induced diabetic rats
g (bw)/d including 2.4 mg monascin and 1.2 mg ankaflavin) and pio-
rmal diet and administered with red mold dioscorea (5, 880 mg/kg
one 2.6 mg/kg; RMD ¼ red mold dioscorea; SD ¼ standard deviation;
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 3 ( 2 0 1 5 ) 7 1 9e7 2 8726significantly higher potassium levels than those in the RMD-
treated groups. Calcium and phosphorus are essential min-
erals found in the bone, blood, and soft tissue of the body, and
have a role in numerous body functions. Similar levels of
serum calcium and phosphorus were noted among groups,
indicating that administration of RMD or RMD with pioglita-
zone has no significant effect on electrolyte balance at any of
the doses studied. Electrolyte levels in the RMD-treated groups
and control group showed no significant difference; thus, it
can be inferred that RMD can improve sodium, potassium, and
chloride levels in the body.4. Discussion
Our study shows that Monascus fermentation using a dio-
scorea substrate results in higher levels of monascin and
ankaflavin [27]. Monascus-fermented products can be used as
food-based adjuvant therapy for diabetic patients to amelio-
rate IR and/or impaired glucose metabolism [18]. In our pre-
vious study, we showed that RMR supplements significantly
reduced serum insulin levels in high-fat-induced rats [28]. Our
current study showed a significant decrease in blood glucose
levels of STZ-induced diabetic rats fed RMD at Week 6 and
Week 8 (Fig. 2C and 2D), providing direct evidence of the
antihyperglycemic effects of RMD.
OGTT is a screening method used to assess acute anti-
hyperglycemic activity [29]. We applied this glucose challenge
test to STZ-induced rats, and by 120 minutes after receiving
oral treatment with RMD, we observed a significant lowering
of plasma glucose levels (Fig. 2). This suggests that com-
pounds present in RMD have effects on glucose absorption
and/or metabolism.
Levels of serum creatinine and BUN are generally consid-
ered as markers of renal function. The diabetic nephropathy
observed in human diabetes usually also occurs in experi-
mental diabetes models. BUN is a type of protein metabolite,
and a high concentration of BUN indicates weak renal excre-
tion. In particular, increased BUN levels would indicate renal
dysfunction. However, administration of RMD or RMD along
with pioglitazone improved the metabolic and physiological
functions of the kidneys of rats in our study. The major
components of RMD (e.g., monascin) may have antidiabetic
effects in STZ-induced diabetic rats [30]. Glycated hemoglobin
(HbA1c) was a useful indicator of mean blood glucose con-
centrations over the preceding 2e3 months. Epidemiological
studies have reported that higher HbA1c values were strongly
associated with microvascular diabetic complications, renal
function, chronic kidney disease, and all-cause mortality in
populations with and without diabetes [31e33].
In 2007, the Food and Drug Administration warned con-
sumers to avoid cholesterol-lowering RMR supplements (RMR,
RMRepolicosanol complex, and Cholestrix) due to the possi-
bility of developing myopathy and kidney dysfunction.
Rhabdomyolysis is characterized by necrosis of skeletal
muscle and the subsequent release of toxic intracellular
components into the systemic circulation [34]. Approximately
26% of patients with rhabdomyolysis cannot be diagnosed on
the basis of urine myoglobin concentrations because of the
low sensitivity of this assay [35]. Elevated CPK levels, whichare used in the diagnosis and monitoring of clinical myocar-
dial infarction and muscle diseases, are also good diagnostic
indicators of rhabdomyolysis. CPK levels increase as early as
2e12 hours after muscle injury, and blood CPK levels remain
high for longer than blood myoglobin levels [36]. Moreover,
abnormally high CPK values of up to 5000 U/L have been re-
ported in cases of rhabdomyolysis [37]. However, we found
that treatment of STZ-induced rats with RMD or RMD with
pioglitazone did not significantly affect CPK values (Table 1).
Potassium and calcium are themost important electrolytes
in the human body [38,39]. The serum glucose concentration
and total carbon dioxide content correlate significantly with
the serum potassium concentration, and the most common
cause of hyperkalemia (potassium overload) is kidney disease
[40]. Previously, it was reported that there was no consistent
or marked decrease in the concentration of sodium and
chloride in rats with diabetes insipidus, however, there was a
typical increase in potassium levels [41]. In comparison with
the nondiabetic rats and the RMD and RMD and pioglitazone
groups, the rats in the vehicle-treated STZ-induced group had
lower sodium and chloride levels and a significantly higher
potassium level (Table 4). In particular, the mean serum so-
dium in the STZ-induced diabetic rats was considerably lower
than that in the nondiabetic rats. Milanov et al [42] ascribed
this drop in serum sodium to diuresis, which ensues from the
diabetic state. In this study, we investigated a number of in-
dicators of kidney function, including plasma electrolytes (i.e.,
sodium and potassium), BUN, and creatine. In particular,
increased BUN levels would indicate renal dysfunction.
However, administration of RMD or RMD along with pioglita-
zone improved the metabolic and physiological functions of
the kidneys of rats in our study.5. Conclusion
The present study showed that RMD attenuated the develop-
ment of diabetes, and alleviated hyperglycemia and IR in STZ-
induced diabetic rats. In comparison with antidiabetic drugs,
RMD has the advantage of being a common food supplement.
Findings from this studymight lend support to the use of RMD
as a novel functional food for the prevention of diabetes.
However, we found that treatment with RMD improved the
indices of diabetes in these rats. In addition, we did not find
any evidence implicating RMD products in rhabdomyolysis.
We showed that administration of five times the recom-
mended dose of RMD did not cause any adverse effects.Conflicts of interest
The authors declare no conflicts of interest.
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